CLOs on the Move

Acucela

www.acucela.com

 
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.acucela.com
  • 1301 2nd Ave # 1900
    Seattle, WA USA 98101
  • Phone: 206.805.8300

Executives

Name Title Contact Details

Similar Companies

TruWin

TruWin, Inc. is a Canonsburg, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

DDB Corbett

DDB Corbett is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WellBiz Brands

Wellbiz Brands, Inc. is the nation`s premiere franchisor of wellness, fitness and beauty brands. With more than 600 locations, WellBiz Brands is uniquely qualified to serve the growing needs of the health and beauty conscious consumer through recurring revenue experience-based brands including Elements Massage®, Amazing Lash Studio® and Fitness Together®. Backed by a management team with nearly a century of combined leadership experience, WellBiz Brands accelerates scalable and predictable revenue growth by providing a robust platform of shared services, infrastructure and support. The company claimed three spots on the 2018 Inc. 5000 Fastest Growing Companies list and is headquartered in Englewood, Colorado.

iCarbonX

iCarbonX is building a digital life ecosystem by combining consumer life data, the Internet and artificial intelligence.

SpectraScience

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT™ Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.